D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity
- 1 July 2003
- Vol. 50 (1) , 7-13
- https://doi.org/10.1002/syn.10239
Abstract
Selegiline (L‐deprenyl) is believed to render protection against l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐neurotoxicity to a significant extent via a free radical scavenging mechanism, which is independent of its ability to inhibit monoamine oxidase‐B (MAO‐B) in the brain. We investigated the hydroxyl radical (.OH) scavenging action and neuroprotective effect of D‐deprenyl, its less active isomer, in MPTP‐induced dopaminergic neurotoxicity in mice to test whether the chemical structure of the molecule or its biological effects contribute to this property. To achieve this goal we studied the effects of D‐deprenyl on: (1) .OH production in a Fenton reaction; (2) MPTP‐induced .OH generation and dopamine (DA) depletion in vivo, employing a sensitive HPLC‐electrochemical procedure; and (3) formation of MPP+ in vivo in the striatum following systemic administration of MPTP, employing an HPLC‐photodiode array detection system. D‐deprenyl inhibited ferrous citrate‐induced .OH in vitro (0.45 μM) and MPTP‐induced .OH in vivo in substantia nigra (SN) and in the striatum (1.0 mg/kg, i.p.). D‐deprenyl did not, but L‐deprenyl (0.5 mg/kg dose) did significantly inhibit formation of MPP+ in the striatum 90 min following systemic MPTP injection. It failed to affect MAO‐B activity at 0.5 mg/kg in the striatum, but effectively blocked MPTP‐induced striatal DA depletion. The potency of D‐deprenyl to scavenge MPTP‐induced .OH in vivo and to render protection against the dopaminergic neurotoxicity without affecting dopamine turnover, MAO‐B activity, or formation of MPP+ in the brain indicates a direct involvement of .OH in the neurotoxic action of MPTP and antioxidant effect in the neuroprotective action of deprenyl. Synapse 50:7–13, 2003.Keywords
This publication has 56 references indexed in Scilit:
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidasePublished by Elsevier ,2004
- An improved fluorimetric assay for brain monoamine oxidasePublished by Elsevier ,2002
- Ferrous‐Citrate Complex and Nigral Degeneration: Evidence for Free‐radical Formation and Lipid PeroxidationaAnnals of the New York Academy of Sciences, 1994
- Antioxidant Mechanism and Protection of Nigral Neurons Against MPP+ Toxicity by Deprenyl (Selegiline)Annals of the New York Academy of Sciences, 1994
- Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptakeNeuropharmacology, 1994
- Resistance of Golden Hamster to l‐Methyl‐4‐Phenyl‐1,2,3,6 Tetrahydropyridine: Relationship with Low Levels of Regional Monoamine Oxidase BJournal of Neurochemistry, 1994
- The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in parkinson's diseaseMovement Disorders, 1993
- The effects of deprenyl on methamphetamine-induced dopamine depletionsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTPNeuroscience Letters, 1987
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984